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PHARMACY
New Guidelines of Clostridium Difficile 
Infection (CDI)
Kashif Hussain, Specialist, Pharmacy Services 
The Infectious Diseases Society of America (IDSA) and the Society for 
Healthcare Epidemiology of America (SHEA) have released updated 
guidelines for Clostridium difficile Infections (CDI). A major change in the 
recommendations is the initial CDI treatment. For the first time in almost 3 
decades, metronidazole is no longer recommended as first-line therapy in adults. 
Instead, oral vancomycin (125 mg, 4 times a day) or fidaxomicin (200 mg twice 
daily) are recommended for 10 days in both non-severe and severe CDI. The 
change in treatment recommendation was made based on evidence to support that 
use of vancomycin or fidaxomicin provide patients with the highest likelihood 
of sustained symptom resolution one month after treatment. In patients with 
non-severe cases of CDI, metronidazole is still recommended when patients are 
unable to obtain or be treated with vancomycin or fidaxomicin.
In patients with severe, complicated CDI with shock, hypotension, ileus, or 
megacolon, vancomycin 500 mg 4 times a day is recommended with parenteral 
metronidazole. Patients with ileus can be administered vancomycin via enema. 
Metronidazole is not recommended for recurrent CDI infections.The guidelines 
do not make a recommendation regarding the role of probiotics.Pharmacists can 
play an important role in ensuring the optimal treatment approach for patients 
with CDI, particularly when it appears that a patient may be being treated for 
CDI according to outdated guidelines.
Reference:
	 l McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for 
	 	 Clostridium	difficile	infection	in	adults	and	children:	2017	update	by	the	Infectious		 	
	 	 Diseases	Society	of	America	(IDSA)	and	Society	for	Healthcare	Epidemiology	of	America	
	 	 (SHEA).	Clin	Infect	Disease.	2018
Drug Incompatibility and Medication Error
Mohd Amir, Specialist, Pharmacy Services
Intravenous medication may interact with other causing physicochemical 
incompatibilities. As a result of it, drug efficacy may be reduced or risk of 
adverse effect may increase, thus causing a medication error. Medication 
incompatibility may cause 20 % of all medication errors and 89% of 
administration errors. Drug incompatibility can be visible ( color change, 
clouding and precipitation) or can be invisible ( pH changes, complex reaction). 
Drug incompatibility can be caused at the time preparation and administration. In 
term of preparation, incompatibility is caused, if a drug is reconstituted or diluted 
with a non-compatible solution or drugs as admixtures. While administration, it 
may be caused as due to Y-site administration or mixing two drugs in a syringes.  
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In this three methods; admixture, Y-site administration and syringe preparation; drugs are allowed time to interact 
with each other and hence may cause incompatibility.  Incompatibility does not exist if drugs are given by central line 
catheter or peripherally inserted central catheter.  Furthermore, incompatibility does not occur, if drugs are given via two 
different arms peripheral lines. With respect to blood, it’s not advisable to administer drug with it from same line.
Reference:
 l		Medication	Error	and	drug	Incompatibility	[Internet].	ELCAM	SAFETY;	Retrieved	from:	http://www.infusesafety.com/medication-
	 	 errors---drug-incompatibility	
Botulinum Toxin Type –A: An Option to Treat Carpal Tunnel 
Syndrome (CTS)
Areeba	Nayab,	Trainee	Pharmacist
Carpal tunnel syndrome (CTS) affects approximately 1–3% of the population. It is a clinical condition in which the 
median nerve of the wrist is entrapped and undergoes irritation, often attributed to compression. CTS is associated with 
a significant increase in interstitial pressure, and a resulting compromise of blood flow. When that pressure persists, the 
symptoms related to CTS appear. Symptoms include paresthesias in the thumb, index, middle and radial half of the ring 
finger, and pain in the hand and wrist that can radiate to the forearm.
Botulinum toxin (BTX) has been successfully used in the treatment of spasmodic torticollis, limb dystonia, and 
spasticity. Botulinum toxins A (Botox, by Allergan, Irvine, CA) and B (Myobloc, by Solstice Neurosciences, San 
Francisco, CA) have recently been used for the management of a variety of painful states (e.g., primary headaches, 
back pain, myofascial pain, painful dystonia The mechanism for their analgesic effect may be related to acetylcholine 
inhibition and/or a blocking action of the release of neuropeptides and glutamate from primary afferents. Botulinum 
toxin type A (BTX-A) paralyzes skeletal muscles by inhibiting the exocytosis of acetylcholine at the cholinergic nerve 
endings of motor nerves, and is also reportedly effective at alleviating various pain conditions, including neuropathic 
pain and headache, independent of its effect on muscle contraction. 
The mechanism underlying the antinociceptive action of BTX-A in neuropathic pain conditions has been hypothesized 
to be related to BTX-A’s noted ability to inhibit the release of several noncholinergic neurotransmitters (including 
substance P, calcitonin gene-related peptide, and glutamate) associated with neurogenic inflammation, and possibly 
peripheral sensitization. As nerve injury induces the release of such agents, peripheral BTX-A treatment might alleviate 
some of the symptoms of neuropathic pain. 
References:
 l	 Breuer	B,	Sperber	K,	Wallenstein	S,	Kiprovski	K,	Calapa	A,	Snow	B,	Pappagallo	M.	Clinically	significant	placebo	analgesic	response	in		
	 	 a	pilot	trial	of	botulinum	B	in	patients	with	hand	pain	and	carpal	tunnel	syndrome.	Pain	medicine.	2006	Jan	1;7(1):16-24.
 l	 Jeynes	LC,	Gauci	CA.	Evidence	for	the	use	of	botulinum	toxin	in	the	chronic	pain	setting—a	review	of	the	literature.	Pain	Practice.	2008		
	 	 Jul	1;8(4):269-76.
 l	 Yoon	SH,	Merrill	RL,	Choi	JH,	Kim	ST.	Use	of	botulinum	toxin	type	A	injection	for	neuropathic	pain	after	trigeminal	nerve	injury.	Pain		
	 	 Medicine.	2010	Mar	31;11(4):630-2.
2
Hydrocortisone Plus Fludrocortisone for Adults with Septic Shock – 
The Latest Approach
Nimra	Iqbal	Surti,	Pharmacist
Septic shock is a dysregulated host body response to an infection concomitantly with circulatory, cellular and metabolic 
abnormalities. Hydrocortisone and Fludrocortisones are corticosteroids that respond as cardiovascular function 
enhancers and anti-inflammatory agents in state of septic shock. 
The multicenter, double-blind, randomized APROCCHSS (Activated Protein C and corticosteroid for Human Septic 
Shock) Clinical trial comprising 1241 patients hypothesized that therapy with hydrocortisone plus fludrocortisone or with 
Pharmacy Newsletter 3
drotrecogin alfa (activated) would improve the clinical outcomes of patients with septic shock through host response 
modulation. The trial compared patients who received hydrocortisone plus fludrocortisone with those who did not (placebo 
group). The Treatment regime of the trial comprised 50mg intravenous bolus of Hydrocortisone every 6 hrs and once daily 
administration of 50-μg tablet of fludrocortisone in morning. However the rate of serious adverse events did not differ 
significantly between the two groups, but hyperglycemia was more common in hydrocortisone-plus-fludrocortisone group.
Hence the APROCCHSS clinical trial concluding in favor of the proposed hypothesis clearly indicates that the 
concomitant use of hydrocortisone with fludrocortisone to treat patients with septic shock using the trial treatment 
regimen will result in favorable clinical outcomes in such patients.
Reference:
	 l	 Djillali	Annane	et	al,	Hydrocortisone	plus	Fludrocortisone	for	Adults	with	Septic	Shock,	N	Engl	J	Med	2018;	378:809-818.
	 l	 Daniel	De	Backer,	Todd	Dorman;	Surviving	Sepsis	Guidelines:	A	Continuous	Move	toward	Better	Care	of	Patients	with	Sepsis	JAMA.	
	 	 2017	Feb	28;	317(8):807-808.
Adverse Drug Reactions (ADR) Reporting Trend at AKUH – Year 2017
Dr Ale zehra, Clinical Pharmacist
Adverse drug reaction (ADR) are any response to a drug that is noxious, unintended and that occurs at doses normally 
used for prophylaxis, diagnosis or therapy. The main purpose of ADR reporting and monitoring is to provide an indirect 
measure of the quality of pharmaceutical care through identification of preventable ADRs and anticipatory surveillance 
for high-risk drugs or patients. The data will help to monitor trends and significant isolated ADRs, create a feedback 
loop to practitioners, promote educational endeavors to prevent ADRs, and improve patient outcomes. 
Year 2017 data shows a total number of 132 ADRs were reported (with exception of many unreported too). Following 
are the details of reported ADRs: Antibiotics: In year 2017, majority of ADRs were reported from Antibiotic and 
Neoplastic class of drugs. These mainly were rashes and hypersensitivity reactions. Learning outcomes are:
 l All antibiotics/neoplastic drugs   must be infused slowly over period time recommended by the drug information 
  resources (mention on the patient labels).
 l  Avoid administration of antibiotics in high concentrations where possible, decrease rate of infusion if using 
  maximum concentration of dilution.
 l If patient develops allergy or hypersensitivity to any antibiotic it must be documented in patient record and 
  updated in the Pharmacy system to avoid any further administration. 
Adverse drug Reactions are reported in AKUH through;
	 l Yellow Cards
	 l http://portal.aku.edu/pharmacy/adrrf.html 
	 l Through ADR Hot line: Ext:1479
¡ Antibiotic ¡ Antineoplastic 
¡ Insulin ¡ NSAIDs
¡ Immunomodulator ¡ Anticoagulants 
¡ Benzodiazepines ¡ Xanthine Oxidase Inhibitor
¡ General anesthetic ¡ Iron preparation 
¡ Antiviral ¡ Miscellaneous
ADR - Year 2017
Total Number of Rx’s in 2017 1,423,257
Total ADR’s Reported 132
Therapeutic Class wise ADR Reporting Trend at AKUH | Year 2017
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The Aga Khan University Hospital, Karachi
Provide us your Valuable Feedback!
To	keep	the	Pharmacy	Newsletter	of	Aga	Khan	University	Hospital	(AKUH)	updated	we	would	like	to	take	your	valuable	feedback.	We	are	grateful	
to	you	for	sparing	few	minutes	of	your	precious	time	to	complete	form	by	below	online	link	or	form	can	be	emailed	to	you	as	well.	Just	drop	us	an	
email	with	subject	Newsletter Feedback.	Email	us	at:drug.information@aku.edu 
Thank	you	in	advance	for	your	feedback!	
Link: 
https://goo.gl/forms/Ghh1Nc2KY2jEkiUL2
Medication Reconciliation: Step to Enter Patient Home Medication 
Entry
Hafsah	Ashfaq,	Clinical	Pharmacist
STEP 01
STEP 02
STEP 03
STEP 04
Message will appear
Medication Reconciliation is an important step for patient 
safety; please update patient’s Past Medication History 
before proceeding with the order
Dr will take decision on each medication as mentioned:
	 • Continue (during admission)
	 • Hold till Discharge
	 • Discontinue 
Drugs to be continued must be entered in the system as a routine order.
1. Upon selection of first 2 options, system will not further prompt the user unless Dr wants to update the list later 
2. Upon selection of last option, system will allow the Dr to proceed with the order but as soon as 24 hrs clock is completed, it will restrict further   
 order entry unless the list is updated.
 Last option should be used if the history:
• Is there but still incomplete,
• Temporarily not available (attendant / last prescription etc. not present)
• Order entry is more critical to stabilize the patient in 1st 24 hrs of admission
• Medication name can be selected in 2 ways:
  o Formulary (as available in AKUH)
  o Choose from predefine list of drugs
• Non Formulary (other brands/products)
  o Free Text Entry
• Proper Dose, frequency and route of administration as described by patient is to be entered 
